Literature DB >> 22370800

[Off-label therapy from the perspective of the medical insurance service].

L Grell1, M Rieger.   

Abstract

The assessment of off-label medications is one of the most common reasons for assessment of drugs for individual patients in the German medical services. Tension is not uncommon because of great expectations of patients and doctors on the one hand and the requirements of the law on the other. They often do not match. Even if there is a medically justified off-label use the road to drug approval is principally via the authorities with tested efficacy and safety in order not to deprive the patient of the protection of the Pharmaceuticals Act. The jurisdiction has approved criteria for reimbursement by the statutory health insurance only in clearly defined exception and one requirement is that there are no alternative forms of treatment. For serious diseases this is based on the evidence of drug approval; however, for immediately life-threatening situations a very low evidence level is sufficient.

Entities:  

Mesh:

Year:  2012        PMID: 22370800     DOI: 10.1007/s00393-011-0900-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  6 in total

1.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Authors:  Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

2.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

3.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

4.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors:  Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

5.  Estrogen plus progestin and the risk of coronary heart disease.

Authors:  JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

6.  Off-label promotion, on-target sales.

Authors:  Adriane Fugh-Berman; Douglas Melnick
Journal:  PLoS Med       Date:  2008-10-28       Impact factor: 11.069

  6 in total
  1 in total

Review 1.  [Off-label use of drugs in pediatric emergencies: limitations and grey areas of drug approval].

Authors:  C G Erker; M Möllmann
Journal:  Anaesthesist       Date:  2013-02       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.